| Literature DB >> 26106275 |
Abstract
BACKGROUND: The patient-centered focus of clinical pharmacy practice which demands nuanced application of specialized knowledge and skills targeted to meeting patient-specific therapeutic needs warrant that the training strategy used for PharmD graduates must empower with the ability to use the higher level cognitive processes and critical thinking effectively in service delivery. However, the historical disposition to learning in the Middle East and among Saudi students appeared heavily focused on rote memorization and recall of memorized facts.Entities:
Keywords: Active pedagogic strategies; Metacognition; Peer-assessment; Saudi Arabia; Self-reflection
Year: 2014 PMID: 26106275 PMCID: PMC4475852 DOI: 10.1016/j.jsps.2014.11.018
Source DB: PubMed Journal: Saudi Pharm J ISSN: 1319-0164 Impact factor: 4.330
The five-year PharmD programme at the College of Clinical Pharmacy, King Faisal University.
| Course no. | Course title | Lectures | Practical | Credit hours | Contact hours | Prerequisite |
|---|---|---|---|---|---|---|
| 2030111 | Pharmacy Orientation | 2 | 0 | 2 | 2 | – |
| 2010111 | Fundamentals of Pharmaceutics | 2 | 1 | 3 | 5 | – |
| 2010112 | Pharm Organic Chemistry-1 | 3 | 1 | 4 | 6 | – |
| 2020111 | Physiology-1 | 2 | 1 | 3 | 5 | – |
| 2020112 | Anatomy & Histology-1 | 1 | 1 | 2 | 4 | – |
| 2020113 | Biochemistry-1 | 2 | 0 | 2 | 2 | – |
| 7401101 | Islamic Faith | 2 | 0 | 2 | 2 | – |
| 2010121 | Physical Pharmacy | 2 | 1 | 3 | 5 | 2010111 |
| 2010122 | Pharmaceutical Analytical Chemistry | 2 | 1 | 3 | 5 | 2010112 |
| 2010123 | Pharm Organic Chemistry-2 | 3 | 0 | 3 | 3 | 2010112 |
| 2020121 | Physiology-2 | 2 | 0 | 2 | 2 | 2020111 |
| 2020122 | Anatomy & Histology-2 | 1 | 1 | 2 | 4 | 2020112 |
| 2020123 | Biochemistry-2 | 2 | 1 | 3 | 5 | 2020113 |
| 2010124 | Pharmacology-1 | 2 | 0 | 2 | 2 | 2020111 |
| 2010211 | Pharmacology-2 | 2 | 1 | 3 | 5 | 2010124 |
| 2010212 | Medicinal Chemistry-1 | 3 | 0 | 3 | 3 | 2010123 |
| 2020211 | Pathophysiology-1 | 2 | 0 | 2 | 2 | 2020111 |
| 2010213 | Pharmacognosy | 2 | 1 | 3 | 5 | – |
| 2020212 | Clinical Biochemistry & Nutrition | 2 | 1 | 3 | 5 | 2020123 |
| 2020213 | Molecular Biology | 2 | 0 | 2 | 2 | – |
| 740130 | Contemporary Cultural issues | 2 | 0 | 2 | 2 | – |
| 2010221 | Pharmacology-3 | 3 | 0 | 3 | 3 | 2020121 |
| 2010222 | Medicinal Chemistry-2 | 3 | 0 | 3 | 3 | 2010212 |
| 2010223 | Pharmaceutical Dosage Forms | 2 | 1 | 3 | 5 | 2010111 |
| 2020221 | Pathophysiology-2 | 2 | 0 | 2 | 2 | 2020121 |
| 2020222 | Immunology | 2 | 0 | 2 | 2 | 2020121 |
| 2020223 | Microbiology | 3 | 1 | 4 | 6 | 2020211 |
| 2030221 | Pharmaceutical Care-1 | 0 | 1 | 1 | 3 | – |
| 2030231 | Introductory Pharmacy Practice Experience in Community Pharmacy (4 weeks, 160 h) | 0 | 2 | 2 | 6 | – |
| 2010311 | Pharmacology-4 | 3 | 0 | 3 | 3 | 2020121 |
| 2010312 | Pharmaceutical Delivery System | 2 | 0 | 2 | 2 | 2010223 |
| 2010313 | Medicinal Chemistry-3 | 2 | 0 | 2 | 2 | 2010222 |
| 2010314 | Bio-pharmaceutics | 2 | 1 | 3 | 5 | – |
| 2030311 | Therapeutics-1 | 4 | 1 | 5 | 7 | 2010211 |
| 2030312 | Pharmaceutical Care-2 | 2 | 1 | 3 | 5 | 2030221 |
| 2030321 | Therapeutics-2 | 4 | 1 | 5 | 7 | 2010221 |
| 2030322 | Pharmaceutical Care-3 | 2 | 0 | 2 | 2 | 2030312 |
| 2030323 | Institutional Pharmacy Practice | 1 | 0 | 1 | 1 | – |
| 2030324 | First Aid and Emergency Medicine | 0 | 1 | 1 | 3 | 2020121 |
| 2010325 | Research Methodology & Biostatistics | 2 | 1 | 3 | 5 | 2020213 |
| 2010321 | Natural Products & Herbal Medicine | 2 | 0 | 2 | 2 | 2010213 |
| 2010322/2010323 | Industrial Pharmacy or Principles of Drug Design ( | 2 | 0 | 2 | 2 | 2010223/2010313 |
| 2030331 | Introductory Pharmacy Practice Experience in Community Pharmacy (4 weeks, 160 h) | 0 | 2 | 2 | 6 | – |
| 2030411 | Law & Ethics in Pharmacy Practice | 1 | 0 | 1 | 1 | 2030111 |
| 2030412 | Therapeutics-3 | 4 | 1 | 5 | 7 | 2010221 |
| 2030413 | Drug Information Services | 2 | 1 | 3 | 5 | 2030311 |
| 2030414 | Clinical Pharmacokinetics | 2 | 1 | 3 | 5 | 2010314 |
| 2030415 | Parenteral Nutrition | 1 | 0 | 1 | 1 | 2020212 |
| 2030416 | Pharmacoeconomics | 1 | 0 | 1 | 1 | – |
| Elective Islamic Course | 2 | 0 | 2 | 2 | – | |
| 2010421 | Clinical Toxicology | 2 | 0 | 2 | 2 | 2010124 |
| 2030421 | Therapeutics-4 | 4 | 1 | 5 | 7 | 2010311 |
| 2030422 | Pharmacy management | 2 | 0 | 2 | 2 | 2030323 |
| 2030423 | Pharm. D. Seminar | 0 | 1 | 1 | 3 | 2030325 |
| 2030424 | Self-care & Nonprescription Drugs | 2 | 0 | 2 | 2 | 2010312 |
| 2030425 | Pharmacoepidemiology | 1 | 0 | 0 | 1 | 2030414 |
| 2020421/2030426 | Pharmaceutical Biotechnology/Pharmacogenomics: | 2 | 0 | 2 | 2 | 2020213/2020213 |
| 2030431 | Advanced Pharmacy Practice Experience-1 | 0 | 5 | 5 | 40 | – |
| 2030511 | Advanced Pharmacy Practice Experience-2 | 0 | 15 | 15 | 120 | – |
| 2030521 | Advanced Pharmacy Practice Experience-3 | 0 | 15 | 15 | 120 | – |
Academic achievements among students in the study and control groups.
| Therapeutics-3 | |||
|---|---|---|---|
| Items | Study group ( | Control group ( | |
| Quizzes (mean ± SD) | 8.2 ± 2.1 | 7.6 ± 1.8 | 0.03 |
| Mid-term exam (mean ± SD) | 18.5 ± 3.7 | 16.9 ± 3.1 | 0.01 |
| Final exam (mean ± SD) | 29.5 2.6 | 27.5 1.9 | 0.01 |
| Total for all assessment tasks | 73.5 ± 3.1 | 69.7 ± 2.8 | 0.01 |
| Percentage pass | 100% | 87.1% | 0.001 |
| Grades obtained ( | |||
| A | 0 (0) | 2 (6.5) | 0.001 |
| B | 7 (31.8) | 3 (9.6) | |
| C | 9 (40.9) | 16 (51.6) | |
| D | 6 (27.2) | 6 (19.4) | |
| F | 0 (0) | 4 (12.9) | |
| Pharmacoeconomics | |||
| Study group ( | Control group ( | ||
| Quizzes (mean ± SD) | 7.2 ± 1.3 | 6.3 ± 2.9 | 0.02 |
| Mid-term exam (mean ± SD) | 31.2 ± 2.4 | 29.3 ± 3.1 | 0.01 |
| Final exam (mean ± SD) | 35.7 ± 3.8 | 32.6 ± 4.2 | 0.01 |
| Total for all assessment tasks | 74.3 ± 4.3 | 68.5 ± 3.6 | 0.001 |
| Percentage pass | 100% | 84.4% | 0.001 |
| Grades obtained ( | |||
| A | 0 (0) | 1 (3.1) | 0.001 |
| B | 8 (36.4) | 4 (12.5) | |
| C | 10 (45.5) | 10 (31.3) | |
| D | 4 (18.2) | 12 (37.5) | |
| F | 0 (0) | 5 (15.6) | |
P ⩽ 0.05 = significant difference.
Grade descriptors: A: 90–100, B: 80–89, C: 70–79, D: 60–69, F: <60.
Independent t-test.
Chi-square test.
Figure 1Histograms and grade distribution curve for students in the study and control groups for Pharmacoeconomics and Therapeutics-3. Grade descriptors: A: 90–100, B: 80–89, C: 70–79, D: 60–69, F: <60.
End-of-course written feedbacks from students for Therapeutics-3 in the study and control groups.
| Items | |
|---|---|
| Developed skills at clinical decision-making and therapeutic planning | 16 (39) |
| Improved critical thinking, greater engagement with the course materials and communication skills | 12 (29.3) |
| Improved knowledge of therapeutics and application of pharmacology in patient management | 11 (26.8) |
| Great but heavy and stressful which sometimes negatively affect social life | 2 (4.9) |
| Good knowledge of pathophysiology, clinical features and improved ability to recommend appropriate treatments | 13 (31) |
| Improved ability to link pathophysiology with clinical features | 9 (21.4) |
| Best learning experience thus far with therapeutics | 9 (21.4) |
| Better focus on understanding rather focus only on memorizing | 6 (14.3) |
| Stressful experience due to heavy content | 4 (9.5) |
| Cleared previous misunderstanding of therapeutics as a course | 1 (2.3) |
End-of-course written feedbacks from students for Pharmacoeconomics in the study and control groups.
| Items | |
|---|---|
| Improved confidence in making drug therapy decisions based on costs and outcomes analysis | 21 (35.6) |
| Developed ability to think in a step-wise manner and make correct decisions | 10 (16.9) |
| Improved communication skills during self-reflections among colleagues | 10 (16.9) |
| Developed my ability to assess other students | 9 (15.3) |
| Good understanding rather than memorizing only | 7 (11.9) |
| Preference for increasing the credit hours for the course to 2 | 2 (3.4) |
| Good knowledge of pharmacoeconomic methods and costs assessment | 20 (31.3) |
| Improved discussion skills with participation in the analysis of pharmacoeconomic studies | 12 (18.8) |
| Improved awareness of the hidden costs of diseases and treatment options | 11 (17.2) |
| More emphasis on the analysis of pharmacoeconomic studies | 9 (14.1) |
| Interesting, practical and easy to follow | 7 (10.9) |
| Enabled linkage of theory with practice | 3 (4.7) |
| Course content should be increased and want to learn more | 2 (3) |